Aller au contenu principal
Profil bibliographique

Hiroaki Furumaki

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

22Publications signalées
216Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Blood transfusion and managementBlood groups and transfusionAcute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesBlood donation and transfusion practices

Les publications récentes

2024 article OpenAlex

The development and evanescence of red blood cell antibodies after transfusion: A multi‐institutional prospective study in Japan

Takaaki Ono, Kaede Ino, Naoki Nemoto, Takahito Shinba et autres

Abstract Background Despite several reports on red blood cell (RBC) alloimmunization, the actual prevalence and factors contributing to RBC alloimmunization in transfused patients remain poorly investigated. We examined the association between clinical factors and the development and evanescence of RBC antibodies after …

jp (code pays fourni par la source)

4 citations Transfusion
Accès ouvert 2023 article OpenAlex

A MULTI-INSTITUTIONAL SURVEY OF IMPLEMENTATION OF ELECTRONIC PATIENT IDENTIFICATION SYSTEMS FOR BLOOD COLLECTION AND ADMINISTRATION

Chiaki Yamada, Keiko Ishizuka, Akari Sugimura, Mitsuki Ohishi et autres

採血前や輸血前での患者照合システムの運用状況と,システムの院内採用後に発生した患者誤認のインシデントおよびアクシデントに関し,多施設アンケート調査を実施した.2020年10月から2022年3月までに26施設より調査票が提出された.採血前は15施設(58%),輸血前は25施設(96%)で患者照合システムが採用されていた.手術室,救急外来,血管造影室等では,システムが導入できていない施設が報告された.システム採用後のインシデントおよびアクシデントは12施設より70例が報告され,うち52例(74%)はシステムを導入している場所で発生した.内容は,別患者から採血した(17例),患者照合せずに輸血した(8例),別患者の血液製剤を輸血した(7例)等であった.52例中41例(79%)では,事例発生時に患者照合システムが適切に使用されていなかった.理由は,患者照合の必要性を知らなかった(9例),患者照合を忘れた(5例),緊急対応のため患者照合をスキップした(3例)等であった.患者照合システムの導入を推進し,確実に患者照合してもらうため,システムの有用性を輸血部門が積極的に臨床側に発信する必要がある.

jp (code pays fourni par la source)

1 citation Japanese Journal of Transfusion and Cell Therapy
2020 article OpenAlex

A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells

Hiroaki Furumaki, Akihiro Takeshita, Hitoshi Ohto, Chiaki Yamada et autres

BACKGROUND AND OBJECTIVES: Anti-CD38 monoclonal antibodies, including daratumumab and isatuximab, often interfere with pretransfusion testing. Dithiothreitol (DTT) treatment of red blood cells (RBCs) negates this interference. However, the optimum DTT concentration and treatment time have not been well defined. Here, we quantified …

jp (code pays fourni par la source)

3 citations Vox Sanguinis
Accès ouvert 2020 article OpenAlex

Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature

Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki et autres

Background: After long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients. Here, the clinical significance of other important prognostic factors was evaluated with …

jp (code pays fourni par la source)

21 citations Cancers
2019 conference-abstract OpenAlex

Optimum DTT Concentration and Treatment Time for CD38 Inactivation on RBCs Analyzed By a Newly-Devised Flow Cytometric Antibody Binding Assay

Hiroaki Furumaki, Akihiro Takeshita, Chiaki Yamada, Harumi Fujihara et autres

Background: Anti-CD38 monoclonal antibodies (MoAbs), including daratumumab and isatuximab, are introduced in the treatment of multiple myeloma (MM). However, CD38 is also expressed on red blood cells (RBCs), so that free anti-CD38 MoAbs in patient sera sometimes binds to test RBCs in …

jp (code pays fourni par la source)

1 citation Blood
Accès ouvert 2019 article OpenAlex

PROSPECTIVE STUDY ON THE EXPRESSION OF IRREGULAR ERYTHROCYTE ANTIBODIES AFTER TRANSFUSION-A PILOT STUDY-

Harumi Fujihara, Keiko Ishizuka, Hiroko Watanabe, Hiroaki Furumaki et autres

不規則抗体検査は,通常赤血球製剤の輸血後には実施しないため,輸血後の各不規則抗体の真の陽性率は不明である.輸血後の不規則抗体の陽性化について多施設共同前方向性研究を企画し,今回はそのパイロット試験を実施した.

jp (code pays fourni par la source)

1 citation Japanese Journal of Transfusion and Cell Therapy
2018 conference-abstract OpenAlex

CD56 Is an Unfavorable Prognostic Factor for Acute Promyelocytic Leukemia: Results By Multivariate Analyses in the JALSG-APL204 Study

Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki et autres

Abstract Background: CD56 expression is reported to be associated with adverse prognosis in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and chemotherapy (Murray et al, 1999, Ferrara et al, 2000, Montesinos et al, 2011, Ono T et …

jp (code pays fourni par la source)

1 citation Blood
2017 conference-abstract OpenAlex

Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia Improved Long Term Relapse-Free Survival: 7-Year Results from a Randomized Controlled Trial, JALSG-APL204

Akihiro Takeshita, Norio Asou, Masamitsu Yanada, Toru Sakura et autres

Abstract Background: Tamibarotene, a new synthetic retinoid, displays (i) approximately 10-fold increased potency over ATRA at inducing in vitro differentiation of NB-4 cells (ii) enhanced chemical stability compared with ATRA (iii) low affinity for cellular RA-binding protein. The clinical efficacy of tamibarotene …

jp (code pays fourni par la source)

0 citations Blood
Accès ouvert 2016 article OpenAlex

SURVEY OF HIGH SCHOOL STUDENT ATTITUDES TO BLOOD DONATION

Akihiro Takeshita, Hiroaki Furumaki, Takayoshi Asai, Michiko Kajiwara et autres

とは献血の将来を考えていく上で重要である.アンケート方式による 50 項目の意識調査を行い,献血に関する高校 生への広報や教育の現状と高校生の意識を調査した. 調査は連結不可能の疫学調査として行い, 35 校中 30 校から協 力が得られ,調査対象 16,333 人のうち 15,521 人(95.0%)より回答を得た.男性49.3%,女性は 49.8% であった. 献血を経験した高校生は 1,198 人(7.7%)で,未経験者は 88.6% であった.疲労感や睡眠不足,ダイエット等は 採血の際に注意すべき生活習慣である.献血可能年齢と体重,献血場所,献血に関わるリスク,血液の海外依存度等

jp (code pays fourni par la source)

2 citations Japanese Journal of Transfusion and Cell Therapy

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.